In­ovio adds two to the lead­er­ship team; Adri­an Woolf­son is out at Sang­amo

→ En­trenched in a le­gal bat­tle with their man­u­fac­tur­er that’s ev­i­dent­ly block­ing them from mak­ing their Covid-19 vac­cine can­di­date, In­ovio is mak­ing some lead­er­ship changes. Gene Kim will be pres­i­dent of In­ovio Asia, while Mam­men (An­za) Mam­men jumps aboard the biotech as SVP, clin­i­cal de­vel­op­ment, and is slat­ed over­see de­vel­op­ment of In­ovio’s DNA vac­cine can­di­date INO-4800.

An ex-CFO at VGX Phar­ma­ceu­ti­cals, Kim had pre­vi­ous­ly been the CFO of AfreecaTV and video game de­vel­op­er We­Made En­ter­tain­ment, both South Ko­re­an com­pa­nies. And Mam­men, who re­tired from the US Army with the rank of colonel, spent more than 6 years at Vi­cal, be­com­ing their SVP, clin­i­cal de­vel­op­ment, and pri­or to that role, was an in­fec­tious dis­ease con­sul­tant and found­ing chief of the DoD’s pan­dem­ic warn­ing team at Fort De­t­rick, MD.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.